LY2794193 (1-30 mg/kg, sc), given 30 min prior to PCP (5 mg/kg, sc) leads a dose-related reduction in ambulations.
LY2794193 (1 mg/ kg; iv) exhibits moderate clearance (18.3 mL/min per kg) and volume of distribution (1.17 L/kg) with a calculated plasma half-life (T 1/2 ) of 3.1 h in Male Sprague-Dawley rats.
LY2794193 (3 mg/kg; sc) leads to the rapid appearance in the plasma (AUC=9.9 μM; C max =6.78 μM; T max =0.44 h) and a calculated bioavailability of 121% in male Sprague-Dawley rats.
Animal Model: | Male Sprague-Dawley rats |
Dosage: | 1, 3, 10, or 30 mg/kg < /td> |
Administration: | Administrated sc; given 30 min prior to PCP (5 mg/kg, sc) |
Result: | A dose-related reduction in ambulations was observed, with the 10 and 30 mg/kg dose groups found to be statistically significant. | < /tr>